Literature DB >> 22334727

Profile of microvolt T-wave alternans testing in 1003 patients hospitalized with heart failure.

Colette E Jackson1, Rachel C Myles, Ioannis K Tsorlalis, Jonathan R Dalzell, Richard J Spooner, John R Rodgers, Vladimir Bezlyak, Nicola Greenlaw, Ian Ford, Stuart M Cobbe, Mark C Petrie, John J V McMurray.   

Abstract

AIMS: Observational studies in selected populations have suggested that microvolt T-wave alternans (MTWA) testing may identify patients with heart failure (HF) at risk of sudden cardiac death. The aims of this study were to investigate the utility of MTWA testing in an unselected population of patients with HF and to evaluate the clinical characteristics associated with the MTWA results. METHODS AND
RESULTS: A total of 1003 patients hospitalized with decompensated HF were enrolled. MTWA testing was planned 1 month post-discharge; 648 patients returned for MTWA testing. Mean age was 70.8 ± 10.6 years and 58% were male. Of these patients who returned, 318 (49%) were ineligible for MTWA testing due to atrial fibrillation (AF), pacemaker dependency, or physical inability to undertake the test. Of the MTWA tests, 100 (30%) were positive, 78 (24%) were negative, and 152 (46%) were indeterminate; 112/152 indeterminate tests (74%) occurred because of failure to achieve target heart rate (HR) due to chronotropic incompetence or physical limitations. There were differences in patient characteristics according to MTWA result. Independent predictors of a negative result included younger age and higher left ventricular ejection fraction (LVEF). Independent predictors of a positive result included higher HR during MTWA testing and lower LVEF. Independent predictors of an indeterminate result included older age and history of previous/paroxysmal AF.
CONCLUSIONS: Only half of patients with HF are eligible for MTWA testing and the most common result is an indeterminate test. Patients with positive and indeterminate tests have different clinical characteristics. MTWA treadmill testing is not widely applicable in typical HF patients and is unlikely to refine risk stratification for sudden death on a population level.

Entities:  

Mesh:

Year:  2012        PMID: 22334727     DOI: 10.1093/eurjhf/hfs010

Source DB:  PubMed          Journal:  Eur J Heart Fail        ISSN: 1388-9842            Impact factor:   15.534


  8 in total

1.  Adherence to prescribed medications in patients with heart failure: insights from liquid chromatography-tandem mass spectrometry-based urine analysis.

Authors:  Joanne Simpson; Colette E Jackson; Caroline Haig; Pardeep S Jhund; Maciej Tomaszewski; Roy S Gardner; Yannis Tsorlalis; Mark C Petrie; John J V McMurray; Iain B Squire; Pankaj Gupta
Journal:  Eur Heart J Cardiovasc Pharmacother       Date:  2021-07-23

2.  The novel urinary proteomic classifier HF1 has similar diagnostic and prognostic utility to BNP in heart failure.

Authors:  Ross T Campbell; Adam Jasilek; Harald Mischak; Esther Nkuipou-Kenfack; Agnieszka Latosinska; Paul I Welsh; Colette E Jackson; Jane Cannon; Alex McConnachie; Christian Delles; John J V McMurray
Journal:  ESC Heart Fail       Date:  2020-05-08

3.  Body surface distribution of T wave alternans is modulated by heart rate and ventricular activation sequence in patients with cardiomyopathy.

Authors:  Behnaz Ghoraani; Adrian M Suszko; Raja J Selvaraj; Anandaraja Subramanian; Sridhar Krishnan; Vijay S Chauhan
Journal:  PLoS One       Date:  2019-04-10       Impact factor: 3.240

4.  Ambulatory ECG-based T-wave alternans and heart rate turbulence can predict cardiac mortality in patients with myocardial infarction with or without diabetes mellitus.

Authors:  Ren Li-na; Fang Xin-hui; Ren Li-dong; Gong Jian; Wang Yong-quan; Qi Guo-xian
Journal:  Cardiovasc Diabetol       Date:  2012-09-06       Impact factor: 9.951

5.  Implementation of guidelines for implantable cardioverter-defibrillator therapy in clinical practice: Which patients do benefit?

Authors:  S C Wijers; B Y M van der Kolk; A E Tuinenburg; P A F Doevendans; M A Vos; M Meine
Journal:  Neth Heart J       Date:  2013-06       Impact factor: 2.380

6.  Usefulness of microvolt T-wave alternans testing in the assessment of all-cause mortality and life-threatening ventricular arrhythmia risk in patients with left ventricular dysfunction.

Authors:  Ludmiła Daniłowicz-Szymanowicz; Małgorzata Szwoch; Alicja Dąbrowska-Kugacka; Maria Dudziak; Dariusz Kozłowski; Grzegorz Raczak
Journal:  Arch Med Sci       Date:  2014-01-10       Impact factor: 3.318

7.  Which patients with heart failure should receive specialist palliative care?

Authors:  Ross T Campbell; Mark C Petrie; Colette E Jackson; Pardeep S Jhund; Ann Wright; Roy S Gardner; Piotr Sonecki; Andrea Pozzi; Paula McSkimming; Alex McConnachie; Fiona Finlay; Patricia Davidson; Martin A Denvir; Miriam J Johnson; Karen J Hogg; John J V McMurray
Journal:  Eur J Heart Fail       Date:  2018-06-28       Impact factor: 15.534

8.  Palliative care needs in patients hospitalized with heart failure (PCHF) study: rationale and design.

Authors:  Ross T Campbell; Colette E Jackson; Ann Wright; Roy S Gardner; Ian Ford; Patricia M Davidson; Martin A Denvir; Karen J Hogg; Miriam J Johnson; Mark C Petrie; John J V McMurray
Journal:  ESC Heart Fail       Date:  2015-03-19
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.